We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.1%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.42B
AUM Growth
-$747M
Cap. Flow
-$166M
Cap. Flow %
-6.88%
Top 10 Hldgs %
25.87%
Holding
144
New
14
Increased
42
Reduced
23
Closed
13

Sector Composition

Rank Sector Weight
1 Healthcare 95.03%
2 Consumer Staples 1.05%
3 Consumer Discretionary 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$16.9B
$117M 4.83%
1,349,500
+71,500
+6% +$7M
ISRG icon
2
Intuitive Surgical
ISRG
$133B
$75.5M 3.12%
457,500
UNH icon
3
UnitedHealth
UNH
$378B
$74.8M 3.09%
300,000
-291,000
-49% -$80.1M
BIIB icon
4
Biogen
BIIB
$30B
$56.9M 2.35%
+180,000
New +$54.6M
IRTC icon
5
iRhythm Holdings
IRTC
$4.03B
$52.5M 2.17%
645,000
+21,000
+3% +$1.74M
BAX icon
6
Baxter International
BAX
$14.3B
$52.4M 2.17%
645,000
+120,000
+23% +$10.4M
EHC icon
7
Encompass Health
EHC
$11.1B
$52.2M 2.16%
1,024,455
HUM icon
8
Humana
HUM
$44.5B
$49.5M 2.05%
157,500
-27,500
-15% -$9.28M
PODD icon
9
Insulet
PODD
$11.6B
$48.4M 2%
292,000
+31,500
+12% +$5.76M
HCA icon
10
HCA Healthcare
HCA
$88B
$46.7M 1.93%
520,000
+52,500
+11% +$6.8M
CNC icon
11
Centene
CNC
$30.9B
$44.6M 1.84%
750,000
+520,200
+226% +$31.6M
ACAD icon
12
Acadia Pharmaceuticals
ACAD
$4.41B
$43.3M 1.79%
1,025,000
+355,000
+53% +$14.6M
BPMC
13
DELISTED
Blueprint Medicines
BPMC
$43.1M 1.78%
737,000
+355,000
+93% +$22.8M
FTSV
14
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$42.7M 1.77%
447,400
-2,600
-0.6% -$157K
ALNY icon
15
Alnylam Pharmaceuticals
ALNY
$29.3B
$41.5M 1.72%
381,500
+17,500
+5% +$2.02M
ZLAB icon
16
Zai Lab
ZLAB
$2.06B
$38.6M 1.6%
750,000
+125,000
+20% +$6.52M
TFX icon
17
Teleflex
TFX
$6.3B
$38.1M 1.57%
130,000
AGIO icon
18
Agios Pharmaceuticals
AGIO
$1.82B
$37.4M 1.55%
1,055,500
+414,000
+65% +$19.1M
EW icon
19
Edwards Lifesciences
EW
$50.7B
$36.6M 1.51%
582,000
+31,500
+6% +$2.27M
PEN icon
20
Penumbra
PEN
$12.7B
$36.3M 1.5%
225,000
-17,500
-7% -$2.95M
BSX icon
21
Boston Scientific
BSX
$70.9B
$35.9M 1.48%
1,100,000
-100,000
-8% -$3.91M
NVRO
22
DELISTED
NEVRO CORP.
NVRO
$34.6M 1.43%
346,000
+67,000
+24% +$8.06M
LKFT
23
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$34.3M 1.42%
175,000
SRPT icon
24
Sarepta Therapeutics
SRPT
$1.62B
$33.8M 1.4%
345,500
RARE icon
25
Ultragenyx Pharmaceutical
RARE
$2.5B
$33.2M 1.37%
747,800
+47,800
+7% +$2.48M

Similar funds

Rock Springs Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rock Springs Capital Management held 144 positions worth $2.42B, down 24% from $3.16B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management withdrew a net $166M in Q1 2020, closing 13 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Rock Springs Capital Management opened a new position in Biogen worth $56.9M.

  • Rock Springs Capital Management's largest Q1 2020 buy was Biogen: 180,000 shares worth $56.9M.
  • Rock Springs Capital Management added most to Applied Therapeutics in Q1 2020, an estimated $33.4M increase.
  • Rock Springs Capital Management's biggest Q1 2020 reduction was UnitedHealth, cutting an estimated $80.1M.
  • Rock Springs Capital Management fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $106M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.42B portfolio in Q1 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q1 2020.
  • Rock Springs Capital Management's portfolio value fell 24% quarter-over-quarter to $2.42B.

Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.